CereGate GmbH is a pioneering neurotechnology company developing a hardware-agnostic computer-brain interface (CBI) platform that enables direct communication with the nervous system. The company focuses on restoring and reimagining human senses through innovative, minimally invasive therapeutic solutions for patients with neurological disorders and sensory deficits. Its technology repurposes existing neuromodulation implants—such as Deep Brain Stimulation (DBS) and Spinal Cord Stimulation (SCS)—to deliver personalized treatments that improve mobility in Parkinson’s disease patients and restore balance in individuals with vestibular disorders. The platform is clinically validated, ethically driven, and designed to integrate seamlessly into current healthcare infrastructures.